Meningiomas are associated with inactivation of NF2/Merlin, but approximately one-third of meningiomas with favorable clinical outcomes retain Merlin expression. Biochemical mechanisms underlying Merlin-intact meningioma growth are incompletely understood, and non-invasive biomarkers that may be used to guide treatment de-escalation or imaging surveillance are lacking. Here, we use single-cell RNA sequencing, proximity-labeling proteomic mass spectrometry, mechanistic and functional approaches, and magnetic resonance imaging (MRI) across meningioma xenografts and patients to define biochemical mechanisms and an imaging biomarker that underlie Merlin-intact meningiomas. We find Merlin serine 13 (S13) dephosphorylation drives meningioma Wnt signaling and tumor growth by attenuating inhibitory interactions with β-catenin and activating the Wnt pathway. MRI analyses show Merlin-intact meningiomas with S13 phosphorylation and favorable clinical outcomes are associated with high apparent diffusion coefficient (ADC). These results define mechanisms underlying a potential imaging biomarker that could be used to guide treatment de-escalation or imaging surveillance for patients with Merlin-intact meningiomas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11383945 | PMC |
| http://dx.doi.org/10.1038/s41467-024-52284-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Impact of MRI-Defined Extent of Resection Across Meningioma DNA Methylation Groups: Re-Evaluating Surgery in the Era of Meningioma Molecular Classification.
Neurosurgery
January 2025
Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Background And Objectives: Extent of resection (EOR) is prognostic for meningioma outcomes. DNA methylation profiling can shed light on biological drivers and therapeutic vulnerabilities. The goal of this study was to re-evaluate the impact of EOR on clinical outcomes across meningioma DNA methylation groups.
View Article and Find Full Text PDFMerlin phosphorylation regulates meningioma Wnt signaling and magnetic resonance imaging features.
Nat Commun
September 2024
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Meningiomas are associated with inactivation of NF2/Merlin, but approximately one-third of meningiomas with favorable clinical outcomes retain Merlin expression. Biochemical mechanisms underlying Merlin-intact meningioma growth are incompletely understood, and non-invasive biomarkers that may be used to guide treatment de-escalation or imaging surveillance are lacking. Here, we use single-cell RNA sequencing, proximity-labeling proteomic mass spectrometry, mechanistic and functional approaches, and magnetic resonance imaging (MRI) across meningioma xenografts and patients to define biochemical mechanisms and an imaging biomarker that underlie Merlin-intact meningiomas.
View Article and Find Full Text PDFRNA splicing as a biomarker and phenotypic driver of meningioma DNA-methylation groups.
Neuro Oncol
December 2024
Institute for Systems Genomics, UConn Health, Farmington, CT, USA.
Article Synopsis
- * The study analyzes RNA sequencing data from 486 meningioma samples across three DNA methylation groups, discovering key splicing alterations that correlate with tumor recurrence and patient outcomes, while also identifying important splicing factors like SRSF1 in Hypermitotic meningiomas.
- * The findings emphasize RNA splicing as a crucial aspect of meningioma characteristics, presenting opportunities for prognostic tools and novel RNA-based therapies targeting identified splicing changes.
Epidemiology, Genetics, and DNA Methylation Grouping of Hyperostotic Meningiomas.
Oper Neurosurg (Hagerstown)
January 2024
Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Background And Objectives: Meningiomas are the most common primary intracranial tumors and are among the only tumors that can form lamellar, hyperostotic bone in the tumor microenvironment. Little is known about the epidemiology or molecular features of hyperostotic meningiomas.
Methods: Using a retrospective database of 342 meningiomas treated with surgery at a single institution, we correlated clinical, tumor-related, targeted next-generation DNA sequencing (n = 39 total, 16 meningioma-induced hyperostosis [MIH]), and surgical variables with the presence of MIH using generalized linear models.
Meningiomas are the most common primary intracranial tumors and are associated with inactivation of the tumor suppressor /Merlin, but one-third of meningiomas retain Merlin expression and typically have favorable clinical outcomes. Biochemical mechanisms underlying Merlin-intact meningioma growth are incompletely understood, and non-invasive biomarkers that predict meningioma outcomes and could be used to guide treatment de-escalation or imaging surveillance of Merlin-intact meningiomas are lacking. Here we integrate single-cell RNA sequencing, proximity-labeling proteomic mass spectrometry, mechanistic and functional approaches, and magnetic resonance imaging (MRI) across meningioma cells, xenografts, and human patients to define biochemical mechanisms and an imaging biomarker that distinguish Merlin-intact meningiomas with favorable clinical outcomes from meningiomas with unfavorable clinical outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!